This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

John Finn, Ph.D.
Chief Scientific Officer at Tome Biosciences


John brings over 20 years of gene therapy experience with a focus on genome editing and delivery technologies. Prior to Tome, John was Vice President of Discovery Research at Codiak Biosciences, where he led the development of a new class of therapeutics based on engineered exosomes. Prior to Codiak, John was Executive Director of Platform Biology and Liver Discovery at Intellia Therapeutics, where he was responsible for the development of viral and non-viral delivery systems and demonstrated the first in vivo systemic administration of CRISPR-based therapeutics. Previously, John served as Director of Research at Arthrogen, developing novel AAV and exosome-based therapeutics. He has served as an American Society of Gene and Cell Therapy (ASGCT) Committee Member for multiple committees, including Nanoagents and Synthetic Formulations; Genome Editing; Immune responses; and Metabolic and Inherited Disease. John trained with Pieter Cullis and Ian MacLachlan and received his PhD in Biochemistry and Molecular Biology from the University of British Columbia and BS in Molecular Biology and Genetics from the University of Guelph. He completed post-doctoral programs in Immunology and Vaccine research at McMaster University (Jonathan Bramson lab) and Hematology and Gene Therapy at the Children’s Hospital of Philadelphia (Kathy High Lab).

Agenda Sessions

  • Integrase Mediated Programmable Genomic Integration (I-PGI)